Tests ERAS-0015 alone or combined in advanced solid tumors
Tests whether ERAS-0015 is safe in adults with advanced solid tumors.
Key facts
- Who runs it
- Erasca, Inc.
- Where
- Atlanta, Aurora, Boston, Fairfax, Houston, New York, Santa Rosa, Sarasota, Tampa, and Tyler, United StatesSee the 10 sitesAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 600 people, planned
- Started
- 5 Jun 2025
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- ERAS-0015
- ERAS-0015 in combination
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that have certain RAS mutations, to test whether ERAS-0015 is safe and tolerable.
- Age
- 18 Years to 99 Years
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic solid tumors. There must be no standard treatment available, or standard treatment is not tolerated, not effective, not accessible, or refused. This does not apply to the newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort.
- Earlier treatment
- People who had a RAS inhibitor before cannot join. Other study therapy within 4 weeks of the first dose, and palliative radiation within 14 days of Cycle 1, Day 1, are not allowed.
- Biomarker or test result
- Tumor type and mutation must be documented before the first dose, for applicable cohorts. The study looks at certain RAS mutations.
Main reasons for not taking part
- Previous treatment with a RAS inhibitor
- Another study therapy within 4 weeks of the first dose of ERAS-0015
- Primary central nervous system (CNS) tumors
- Surgery or bowel disease that may affect how the drug is absorbed
- Pregnant or breastfeeding, or expecting to conceive or father children during the trial
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥ 18 years
- Willing and able to give written informed consent
- Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts
- There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort
- Able to swallow oral medication
- Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Adequate cardiovascular, hematological, liver, and renal function
- Willing to comply with all protocol-required visits, assessments, and procedures
Who cannot take part
- Previous treatment with a RAS inhibitor
- Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015
- Received prior palliative radiation within 14 days of Cycle 1, Day 1
- Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
- Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
- Have primary central nervous system (CNS) tumors
- Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
Also in 2 other countries, 3 sites
- Emory UniversityAtlanta, United StatesContact: Erasca Clinical Team TeamTaking people
- University of ColoradoAurora, United StatesContact: Erasca Clinical Team TeamTaking people
- Massachusetts General Hospital (MG)Boston, United StatesContact: Erasca Clinical Team TeamTaking people
- NEXT VirginiaFairfax, United StatesContact: Erasca Clinical Team TeamTaking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Erasca Clinical Team TeamTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Erasca Clinical Team TeamTaking people
- Providence Medical GroupSanta Rosa, United StatesContact: Erasca Clinical Team TeamTaking people
- Florida Cancer SpecalistsSarasota, United StatesContact: Erasca Clinical Team TeamTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Erasca Clinical Team TeamTaking people
- University of Texas at TylerTyler, United StatesContact: Erasca Clinical Team TeamTaking people
About the trial
What the trial wants to find out
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
The 2 groups in the trial
- ERAS-0015 Monotherapy Dose Optimization.Treatment being tested
Escalating doses of ERAS-0015 administered orally.
Treatment: ERAS-0015
- ERAS-0015 Combination Dose OptimizationTreatment being tested
ERAS-0015 administered orally with another investigational agent.
Treatment: ERAS-0015 in combination
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors
- Plain-language title
- Tests ERAS-0015 alone or combined in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06983743, who can take part
- Record updated
- 6 November 2026